{"pmid":32366817,"pmcid":"PMC7198537","title":"A human monoclonal antibody blocking SARS-CoV-2 infection.","text":["A human monoclonal antibody blocking SARS-CoV-2 infection.","The emergence of the novel human coronavirus SARS-CoV-2 in Wuhan, China has caused a worldwide epidemic of respiratory disease (COVID-19). Vaccines and targeted therapeutics for treatment of this disease are currently lacking. Here we report a human monoclonal antibody that neutralizes SARS-CoV-2 (and SARS-CoV) in cell culture. This cross-neutralizing antibody targets a communal epitope on these viruses and may offer potential for prevention and treatment of COVID-19.","Nat Commun","Wang, Chunyan","Li, Wentao","Drabek, Dubravka","Okba, Nisreen M A","van Haperen, Rien","Osterhaus, Albert D M E","van Kuppeveld, Frank J M","Haagmans, Bart L","Grosveld, Frank","Bosch, Berend-Jan","32366817"],"abstract":["The emergence of the novel human coronavirus SARS-CoV-2 in Wuhan, China has caused a worldwide epidemic of respiratory disease (COVID-19). Vaccines and targeted therapeutics for treatment of this disease are currently lacking. Here we report a human monoclonal antibody that neutralizes SARS-CoV-2 (and SARS-CoV) in cell culture. This cross-neutralizing antibody targets a communal epitope on these viruses and may offer potential for prevention and treatment of COVID-19."],"journal":"Nat Commun","authors":["Wang, Chunyan","Li, Wentao","Drabek, Dubravka","Okba, Nisreen M A","van Haperen, Rien","Osterhaus, Albert D M E","van Kuppeveld, Frank J M","Haagmans, Bart L","Grosveld, Frank","Bosch, Berend-Jan"],"date":"2020-05-06T11:00:00Z","year":2020,"_id":"32366817","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1038/s41467-020-16256-y","locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138496119603201,"score":9.490897,"similar":[{"pmid":32065055,"pmcid":"PMC7048180","title":"Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody.","text":["Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody.","The newly identified 2019 novel coronavirus (2019-nCoV) has caused more than 11,900 laboratory-confirmed human infections, including 259 deaths, posing a serious threat to human health. Currently, however, there is no specific antiviral treatment or vaccine. Considering the relatively high identity of receptor-binding domain (RBD) in 2019-nCoV and SARS-CoV, it is urgent to assess the cross-reactivity of anti-SARS CoV antibodies with 2019-nCoV spike protein, which could have important implications for rapid development of vaccines and therapeutic antibodies against 2019-nCoV. Here, we report for the first time that a SARS-CoV-specific human monoclonal antibody, CR3022, could bind potently with 2019-nCoV RBD (KD of 6.3 nM). The epitope of CR3022 does not overlap with the ACE2 binding site within 2019-nCoV RBD. These results suggest that CR3022 may have the potential to be developed as candidate therapeutics, alone or in combination with other neutralizing antibodies, for the prevention and treatment of 2019-nCoV infections. Interestingly, some of the most potent SARS-CoV-specific neutralizing antibodies (e.g. m396, CR3014) that target the ACE2 binding site of SARS-CoV failed to bind 2019-nCoV spike protein, implying that the difference in the RBD of SARS-CoV and 2019-nCoV has a critical impact for the cross-reactivity of neutralizing antibodies, and that it is still necessary to develop novel monoclonal antibodies that could bind specifically to 2019-nCoV RBD.","Emerg Microbes Infect","Tian, Xiaolong","Li, Cheng","Huang, Ailing","Xia, Shuai","Lu, Sicong","Shi, Zhengli","Lu, Lu","Jiang, Shibo","Yang, Zhenlin","Wu, Yanling","Ying, Tianlei","32065055"],"abstract":["The newly identified 2019 novel coronavirus (2019-nCoV) has caused more than 11,900 laboratory-confirmed human infections, including 259 deaths, posing a serious threat to human health. Currently, however, there is no specific antiviral treatment or vaccine. Considering the relatively high identity of receptor-binding domain (RBD) in 2019-nCoV and SARS-CoV, it is urgent to assess the cross-reactivity of anti-SARS CoV antibodies with 2019-nCoV spike protein, which could have important implications for rapid development of vaccines and therapeutic antibodies against 2019-nCoV. Here, we report for the first time that a SARS-CoV-specific human monoclonal antibody, CR3022, could bind potently with 2019-nCoV RBD (KD of 6.3 nM). The epitope of CR3022 does not overlap with the ACE2 binding site within 2019-nCoV RBD. These results suggest that CR3022 may have the potential to be developed as candidate therapeutics, alone or in combination with other neutralizing antibodies, for the prevention and treatment of 2019-nCoV infections. Interestingly, some of the most potent SARS-CoV-specific neutralizing antibodies (e.g. m396, CR3014) that target the ACE2 binding site of SARS-CoV failed to bind 2019-nCoV spike protein, implying that the difference in the RBD of SARS-CoV and 2019-nCoV has a critical impact for the cross-reactivity of neutralizing antibodies, and that it is still necessary to develop novel monoclonal antibodies that could bind specifically to 2019-nCoV RBD."],"journal":"Emerg Microbes Infect","authors":["Tian, Xiaolong","Li, Cheng","Huang, Ailing","Xia, Shuai","Lu, Sicong","Shi, Zhengli","Lu, Lu","Jiang, Shibo","Yang, Zhenlin","Wu, Yanling","Ying, Tianlei"],"date":"2020-02-18T11:00:00Z","year":2020,"_id":"32065055","source":"PubMed","week":"20208|Feb 17 - Feb 23","doi":"10.1080/22221751.2020.1729069","keywords":["2019-ncov","ace2","rbd","sars-cov","monoclonal antibody"],"link_comment_in":"32132669","topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138490837925889,"score":237.07765},{"pmid":32422645,"title":"Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.","text":["Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.","SARS-CoV-2 is a newly emerged coronavirus responsible for the current COVID-19 pandemic that has resulted in more than 3.7 million infections and 260,000 deaths as of 6 May 2020(1,2). Vaccine and therapeutic discovery efforts are paramount to curb the pandemic spread of this zoonotic virus. The SARS-CoV-2 spike (S) glycoprotein promotes entry into host cells and is the main target of neutralizing antibodies. Here we describe multiple monoclonal antibodies targeting SARS-CoV-2 S identified from memory B cells of an individual who was infected with SARS-CoV in 2003. One antibody, named S309, potently neutralizes SARS-CoV-2 and SARS-CoV pseudoviruses as well as authentic SARS-CoV-2 by engaging the S receptor-binding domain. Using cryo-electron microscopy and binding assays, we show that S309 recognizes a glycan-containing epitope that is conserved within the sarbecovirus subgenus, without competing with receptor attachment. Antibody cocktails including S309 along with other antibodies identified here further enhanced SARS-CoV-2 neutralization and may limit the emergence of neutralization-escape mutants. These results pave the way for using S309- and S309-containing antibody cocktails for prophylaxis in individuals at high risk of exposure or as a post-exposure therapy to limit or treat severe disease.","Nature","Pinto, Dora","Park, Young-Jun","Beltramello, Martina","Walls, Alexandra C","Tortorici, M Alejandra","Bianchi, Siro","Jaconi, Stefano","Culap, Katja","Zatta, Fabrizia","De Marco, Anna","Peter, Alessia","Guarino, Barbara","Spreafico, Roberto","Cameroni, Elisabetta","Case, James Brett","Chen, Rita E","Havenar-Daughton, Colin","Snell, Gyorgy","Telenti, Amalio","Virgin, Herbert W","Lanzavecchia, Antonio","Diamond, Michael S","Fink, Katja","Veesler, David","Corti, Davide","32422645"],"abstract":["SARS-CoV-2 is a newly emerged coronavirus responsible for the current COVID-19 pandemic that has resulted in more than 3.7 million infections and 260,000 deaths as of 6 May 2020(1,2). Vaccine and therapeutic discovery efforts are paramount to curb the pandemic spread of this zoonotic virus. The SARS-CoV-2 spike (S) glycoprotein promotes entry into host cells and is the main target of neutralizing antibodies. Here we describe multiple monoclonal antibodies targeting SARS-CoV-2 S identified from memory B cells of an individual who was infected with SARS-CoV in 2003. One antibody, named S309, potently neutralizes SARS-CoV-2 and SARS-CoV pseudoviruses as well as authentic SARS-CoV-2 by engaging the S receptor-binding domain. Using cryo-electron microscopy and binding assays, we show that S309 recognizes a glycan-containing epitope that is conserved within the sarbecovirus subgenus, without competing with receptor attachment. Antibody cocktails including S309 along with other antibodies identified here further enhanced SARS-CoV-2 neutralization and may limit the emergence of neutralization-escape mutants. These results pave the way for using S309- and S309-containing antibody cocktails for prophylaxis in individuals at high risk of exposure or as a post-exposure therapy to limit or treat severe disease."],"journal":"Nature","authors":["Pinto, Dora","Park, Young-Jun","Beltramello, Martina","Walls, Alexandra C","Tortorici, M Alejandra","Bianchi, Siro","Jaconi, Stefano","Culap, Katja","Zatta, Fabrizia","De Marco, Anna","Peter, Alessia","Guarino, Barbara","Spreafico, Roberto","Cameroni, Elisabetta","Case, James Brett","Chen, Rita E","Havenar-Daughton, Colin","Snell, Gyorgy","Telenti, Amalio","Virgin, Herbert W","Lanzavecchia, Antonio","Diamond, Michael S","Fink, Katja","Veesler, David","Corti, Davide"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32422645","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1038/s41586-020-2349-y","e_drugs":["Polysaccharides"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667254896791912448,"score":234.26598},{"pmid":32404477,"title":"A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2.","text":["A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2.","Neutralizing antibodies could be antivirals against COVID-19 pandemics. Here, we report isolation of four human-origin monoclonal antibodies from a convalescent patient, all of which display neutralization abilities. B38 and H4 block the binding between virus S-protein RBD and cellular receptor ACE2. A competition assay indicates their different epitopes on the RBD, making them a potential virus-targeting MAb-pair to avoid immune escape in future clinical applications. Moreover, a therapeutic study in a mouse model validated that these antibodies can reduce virus titers in infected lungs. The RBD-B38 complex structure revealed that most residues on the epitope overlap with the RBD-ACE2 binding interface, explaining the blocking effect and neutralizing capacity. Our results highlight the promise of antibody-based therapeutics and provide a structural basis for rational vaccine design.","Science","Wu, Yan","Wang, Feiran","Shen, Chenguang","Peng, Weiyu","Li, Delin","Zhao, Cheng","Li, Zhaohui","Li, Shihua","Bi, Yuhai","Yang, Yang","Gong, Yuhuan","Xiao, Haixia","Fan, Zheng","Tan, Shuguang","Wu, Guizhen","Tan, Wenjie","Lu, Xuancheng","Fan, Changfa","Wang, Qihui","Liu, Yingxia","Zhang, Chen","Qi, Jianxun","Gao, George Fu","Gao, Feng","Liu, Lei","32404477"],"abstract":["Neutralizing antibodies could be antivirals against COVID-19 pandemics. Here, we report isolation of four human-origin monoclonal antibodies from a convalescent patient, all of which display neutralization abilities. B38 and H4 block the binding between virus S-protein RBD and cellular receptor ACE2. A competition assay indicates their different epitopes on the RBD, making them a potential virus-targeting MAb-pair to avoid immune escape in future clinical applications. Moreover, a therapeutic study in a mouse model validated that these antibodies can reduce virus titers in infected lungs. The RBD-B38 complex structure revealed that most residues on the epitope overlap with the RBD-ACE2 binding interface, explaining the blocking effect and neutralizing capacity. Our results highlight the promise of antibody-based therapeutics and provide a structural basis for rational vaccine design."],"journal":"Science","authors":["Wu, Yan","Wang, Feiran","Shen, Chenguang","Peng, Weiyu","Li, Delin","Zhao, Cheng","Li, Zhaohui","Li, Shihua","Bi, Yuhai","Yang, Yang","Gong, Yuhuan","Xiao, Haixia","Fan, Zheng","Tan, Shuguang","Wu, Guizhen","Tan, Wenjie","Lu, Xuancheng","Fan, Changfa","Wang, Qihui","Liu, Yingxia","Zhang, Chen","Qi, Jianxun","Gao, George Fu","Gao, Feng","Liu, Lei"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32404477","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1126/science.abc2241","topics":["Treatment","Mechanism"],"weight":1,"_version_":1666802845583671298,"score":209.30208},{"pmid":32415260,"title":"Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies.","text":["Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies.","Coronavirus disease 2019 (COVID-19), caused by the novel human coronavirus SARS-CoV-2, is currently a major threat to public health worldwide. The viral spike protein binds the host receptor angiotensin-converting enzyme 2 (ACE2) via the receptor-binding domain (RBD), and thus is believed to be a major target to block viral entry. Both SARS-CoV-2 and SARS-CoV share this mechanism. Here we functionally analyzed the key amino acid residues located within receptor binding motif of RBD that may interact with human ACE2 and available neutralizing antibodies. The in vivo experiments showed that immunization with either the SARS-CoV RBD or SARS-CoV-2 RBD was able to induce strong clade-specific neutralizing antibodies in mice; however, the cross-neutralizing activity was much weaker, indicating that there are distinct antigenic features in the RBDs of the two viruses. This finding was confirmed with the available neutralizing monoclonal antibodies against SARS-CoV or SARS-CoV-2. It is worth noting that a newly developed SARS-CoV-2 human antibody, HA001, was able to neutralize SARS-CoV-2, but failed to recognize SARS-CoV. Moreover, the potential epitope residues of HA001 were identified as A475 and F486 in the SARS-CoV-2 RBD, representing new binding sites for neutralizing antibodies. Overall, our study has revealed the presence of different key epitopes between SARS-CoV and SARS-CoV-2, which indicates the necessity to develop new prophylactic vaccine and antibody drugs for specific control of the COVID-19 pandemic although the available agents obtained from the SARS-CoV study are unneglectable.","Cell Mol Immunol","Yi, Chunyan","Sun, Xiaoyu","Ye, Jing","Ding, Longfei","Liu, Meiqin","Yang, Zhuo","Lu, Xiao","Zhang, Yaguang","Ma, Liyang","Gu, Wangpeng","Qu, Aidong","Xu, Jianqing","Shi, Zhengli","Ling, Zhiyang","Sun, Bing","32415260"],"abstract":["Coronavirus disease 2019 (COVID-19), caused by the novel human coronavirus SARS-CoV-2, is currently a major threat to public health worldwide. The viral spike protein binds the host receptor angiotensin-converting enzyme 2 (ACE2) via the receptor-binding domain (RBD), and thus is believed to be a major target to block viral entry. Both SARS-CoV-2 and SARS-CoV share this mechanism. Here we functionally analyzed the key amino acid residues located within receptor binding motif of RBD that may interact with human ACE2 and available neutralizing antibodies. The in vivo experiments showed that immunization with either the SARS-CoV RBD or SARS-CoV-2 RBD was able to induce strong clade-specific neutralizing antibodies in mice; however, the cross-neutralizing activity was much weaker, indicating that there are distinct antigenic features in the RBDs of the two viruses. This finding was confirmed with the available neutralizing monoclonal antibodies against SARS-CoV or SARS-CoV-2. It is worth noting that a newly developed SARS-CoV-2 human antibody, HA001, was able to neutralize SARS-CoV-2, but failed to recognize SARS-CoV. Moreover, the potential epitope residues of HA001 were identified as A475 and F486 in the SARS-CoV-2 RBD, representing new binding sites for neutralizing antibodies. Overall, our study has revealed the presence of different key epitopes between SARS-CoV and SARS-CoV-2, which indicates the necessity to develop new prophylactic vaccine and antibody drugs for specific control of the COVID-19 pandemic although the available agents obtained from the SARS-CoV study are unneglectable."],"journal":"Cell Mol Immunol","authors":["Yi, Chunyan","Sun, Xiaoyu","Ye, Jing","Ding, Longfei","Liu, Meiqin","Yang, Zhuo","Lu, Xiao","Zhang, Yaguang","Ma, Liyang","Gu, Wangpeng","Qu, Aidong","Xu, Jianqing","Shi, Zhengli","Ling, Zhiyang","Sun, Bing"],"date":"2020-05-17T11:00:00Z","year":2020,"_id":"32415260","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1038/s41423-020-0458-z","keywords":["sars-cov-2","cross-neutralizing antibody","receptor binding motif","spike protein","substitution mutation"],"locations":["vivo"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666991242711400449,"score":205.05829},{"pmid":32134278,"title":"Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19).","text":["Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19).","Last decade witnessed the outbreak of many life-threatening human pathogens including Nipah, Ebola, Chikungunya, Zika, Middle East respiratory syndrome coronavirus (MERS-CoV), Severe Acute respiratory syndrome coronavirus (SARS-CoV) and more recently novel coronavirus (2019-nCoV or SARS-CoV-2). The disease condition associated with novel coronavirus, referred to as Coronavirus disease (COVID-19). The emergence of novel coronavirus in 2019 in Wuhan, China marked the third highly pathogenic coronavirus infecting humans in the 21st century. The continuing emergence of coronaviruses at regular intervals poses a significant threat to human health and economy. Ironically, even after a decade of research on coronavirus, still there are no licensed vaccines or therapeutic agents to treat coronavirus infection which highlights an urgent need to develop effective vaccines or post-exposure prophylaxis to prevent future epidemics. Several clinical, genetic and epidemiological features of COVID-19 resemble SARS-CoV infection. Hence, the research advancements on SARS-CoV treatment might help scientific community in quick understanding of this virus pathogenesis and develop effective therapeutic/prophylactic agents to treat and prevent this infection. Monoclonal antibodies represent the major class of biotherapeutics for passive immunotherapy to fight against viral infection. The therapeutic potential of monoclonal antibodies has been well recognized in the treatment of many diseases. Here, we summarize the potential monoclonal antibody based therapeutic intervention for COVID-19 by considering the existing knowledge on the neutralizing monoclonal antibodies against similar coronaviruses SARS-CoV and MERS-CoV. Further research on COVID-19 pathogenesis could identify appropriate therapeutic targets to develop specific anti-virals against this newly emerging pathogen.","Asian Pac J Allergy Immunol","Shanmugaraj, Balamurugan","Siriwattananon, Konlavat","Wangkanont, Kittikhun","Phoolcharoen, Waranyoo","32134278"],"abstract":["Last decade witnessed the outbreak of many life-threatening human pathogens including Nipah, Ebola, Chikungunya, Zika, Middle East respiratory syndrome coronavirus (MERS-CoV), Severe Acute respiratory syndrome coronavirus (SARS-CoV) and more recently novel coronavirus (2019-nCoV or SARS-CoV-2). The disease condition associated with novel coronavirus, referred to as Coronavirus disease (COVID-19). The emergence of novel coronavirus in 2019 in Wuhan, China marked the third highly pathogenic coronavirus infecting humans in the 21st century. The continuing emergence of coronaviruses at regular intervals poses a significant threat to human health and economy. Ironically, even after a decade of research on coronavirus, still there are no licensed vaccines or therapeutic agents to treat coronavirus infection which highlights an urgent need to develop effective vaccines or post-exposure prophylaxis to prevent future epidemics. Several clinical, genetic and epidemiological features of COVID-19 resemble SARS-CoV infection. Hence, the research advancements on SARS-CoV treatment might help scientific community in quick understanding of this virus pathogenesis and develop effective therapeutic/prophylactic agents to treat and prevent this infection. Monoclonal antibodies represent the major class of biotherapeutics for passive immunotherapy to fight against viral infection. The therapeutic potential of monoclonal antibodies has been well recognized in the treatment of many diseases. Here, we summarize the potential monoclonal antibody based therapeutic intervention for COVID-19 by considering the existing knowledge on the neutralizing monoclonal antibodies against similar coronaviruses SARS-CoV and MERS-CoV. Further research on COVID-19 pathogenesis could identify appropriate therapeutic targets to develop specific anti-virals against this newly emerging pathogen."],"journal":"Asian Pac J Allergy Immunol","authors":["Shanmugaraj, Balamurugan","Siriwattananon, Konlavat","Wangkanont, Kittikhun","Phoolcharoen, Waranyoo"],"date":"2020-03-06T11:00:00Z","year":2020,"_id":"32134278","source":"PubMed","week":"202010|Mar 02 - Mar 08","doi":"10.12932/AP-200220-0773","locations":["Chikungunya","Zika","Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138490707902464,"score":200.94772}]}